These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-alpha convertase. Lee MH; Knäuper V; Becherer JD; Murphy G Biochem Biophys Res Commun; 2001 Jan; 280(3):945-50. PubMed ID: 11162616 [TBL] [Abstract][Full Text] [Related]
5. The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3. Lee MH; Verma V; Maskos K; Becherer JD; Knäuper V; Dodds P; Amour A; Murphy G FEBS Lett; 2002 Jun; 520(1-3):102-6. PubMed ID: 12044879 [TBL] [Abstract][Full Text] [Related]
6. Tailoring tissue inhibitor of metalloproteinases-3 to overcome the weakening effects of the cysteine-rich domains of tumour necrosis factor-alpha converting enzyme. Lee MH; Dodds P; Verma V; Maskos K; Knäuper V; Murphy G Biochem J; 2003 Apr; 371(Pt 2):369-76. PubMed ID: 12556225 [TBL] [Abstract][Full Text] [Related]
7. TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats. Tang ZY; Loss G; Carmody I; Cohen AJ Transplantation; 2006 Dec; 82(11):1518-23. PubMed ID: 17164725 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of the metalloproteinase domain of mouse TACE. Amour A; Hutton M; Knäuper V; Slocombe PM; Webster A; Butler M; Knight CG; Smith BJ; Docherty AJ; Murphy G Ann N Y Acad Sci; 1999 Jun; 878():728-31. PubMed ID: 10415820 [No Abstract] [Full Text] [Related]
9. Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme. Wei S; Kashiwagi M; Kota S; Xie Z; Nagase H; Brew K J Biol Chem; 2005 Sep; 280(38):32877-82. PubMed ID: 16079149 [TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases and TACE play a role in the pathogenesis of endometriosis. Gottschalk C; Malberg K; Arndt M; Schmitt J; Roessner A; Schultze D; Kleinstein J; Ansorge S Adv Exp Med Biol; 2000; 477():483-6. PubMed ID: 10849774 [TBL] [Abstract][Full Text] [Related]
12. Tissue inhibitor of metalloproteinases-3 inhibits shedding of L-selectin from leukocytes. Borland G; Murphy G; Ager A J Biol Chem; 1999 Jan; 274(5):2810-5. PubMed ID: 9915814 [TBL] [Abstract][Full Text] [Related]
13. Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}-converting enzyme. Lee MH; Rapti M; Murphy G J Biol Chem; 2005 Apr; 280(16):15967-75. PubMed ID: 15713681 [TBL] [Abstract][Full Text] [Related]
14. Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity. Solomon A; Rosenblum G; Gonzales PE; Leonard JD; Mobashery S; Milla ME; Sagi I J Biol Chem; 2004 Jul; 279(30):31646-54. PubMed ID: 15102849 [TBL] [Abstract][Full Text] [Related]
15. Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. Solomon KA; Pesti N; Wu G; Newton RC J Immunol; 1999 Oct; 163(8):4105-8. PubMed ID: 10510344 [TBL] [Abstract][Full Text] [Related]
16. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. Amour A; Knight CG; Webster A; Slocombe PM; Stephens PE; Knäuper V; Docherty AJ; Murphy G FEBS Lett; 2000 May; 473(3):275-9. PubMed ID: 10818225 [TBL] [Abstract][Full Text] [Related]
17. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. Amour A; Knight CG; English WR; Webster A; Slocombe PM; Knäuper V; Docherty AJ; Becherer JD; Blobel CP; Murphy G FEBS Lett; 2002 Jul; 524(1-3):154-8. PubMed ID: 12135759 [TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605 [TBL] [Abstract][Full Text] [Related]